Logo of Neuren Pharmaceuticals (ASX:NEU)Latest Neuren Pharmaceuticals (ASX:NEU) News

Page 1
Page 1 of 5

Market Wrap - Week 45 (2 Nov -> 6 Nov) 2026

NEXTDC, Vintage Energy and Embelton recorded the week’s biggest moves, but each came with a different reason and level of risk.
Across resources, takeovers and healthcare, investors rewarded firm deals while selling companies that still need cash or approvals.
Logan Eniac
7 Nov 2026

Neuren upgrades trofinetide income guidance after DAYBUE sales jump

Neuren has lifted its 2026 trofinetide income guidance to US$91 million-US$93 million after Acadia reported a 39% rise in Q3 DAYBUE sales and a US$35 million German launch milestone. Japan trial results also support a planned 2027 regulatory filing, although a launch remains subject to approval and a distribution partner.
Victor Sage
5 Nov 2026

Neuren wins FDA orphan designation for NNZ-2591 in neonatal brain injury

The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.
Victor Sage
2 Nov 2026

Healthcare Wrap - Week 40 (28 Sept -> 2 Oct) 2026

Clinical setbacks and cash shortages weighed on healthcare shares, while selected companies advanced on sales, regulatory and patent news.
Investors now face a simple test: which businesses can turn their latest announcements into funded operations and revenue?
Logan Eniac
3 Oct 2026

Neuren secures potential five-year extension to trofinetide patent protection

Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.
Ada Torres
29 Sept 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Neuren’s Royalties Climb as Profit Dips Amid Phase 3 Push and Dividend Debut

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.
Ada Torres
26 Aug 2026

European Commission Approves DAYBU for Rett Syndrome, Unlocking Milestone Payments for Neuren

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.
Victor Sage
25 Aug 2026

Market Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Small-cap resources stocks led the week, while takeover activity and strong company results added to the gains. Wellnex Life more than doubled, but sharp falls in Trek Metals and Ionic Rare Earths showed that positive news did not always bring buyers.
Logan Eniac
8 Aug 2026

Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
Logan Eniac
8 Aug 2026

Neuren’s DAYBUE Sales Surge 30% in Q2, Lifting 2026 Royalty Forecast

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.
Victor Sage
5 Aug 2026

Market Wrap - Week 27 (29 June -> 3 July) 2026

A tiny gold explorer, a battery materials stock and a biotech name led a week packed with dealmaking, drilling news and fresh funding. Resources did most of the heavy lifting, while several big gaps either held firm or gave back part of their early jump.
Logan Eniac
4 July 2026